Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.
The addition of the EGFR inhibitor nimotuzumab to a chemoradiotherapy (CRT) regimen using cisplatin improved progression-free survival (PFS) and disease-free survival (DFS) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) compared with CRT alone, according to data from a phase III trial presented at ASCO 2018.
Patients with metastatic clear-cell renal cell carcinoma (mRCC) who received sunitinib appeared to have comparable overall survival (OS) with those who received sunitinib after undergoing cytoreductive nephrectomy, according to the phase III CARMENA* trial.
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
The antibody-drug conjugate enfortumab vedotin (EV) demonstrated a promising overall response rate (ORR) in patients with metastatic urothelial cancer (mUC), including those who had liver metastases and prior treatment with checkpoint inhibitors, according to the phase 1 data of the EV-101* trial presented at ASCO 2018.
The combination of ribociclib, a CDK*4/6 inhibitor, and fulvestrant significantly improves progression-free survival (PFS) in post-menopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, according to the MONALEESA-3** study presented at ASCO 2018.
Adding atezolizumab to a combination therapy of bevacizumab plus carboplatin and paclitaxel (CP) significantly improves progression-free survival (PFS) and overall survival (OS) in chemotherapy-naïve patients with metastatic nonsquamous non-small–cell lung cancer (NSCLC), irrespective of PD-L1 expression levels and EGFR or ALK alteration status, according to the IMpower150* trial presented at ASCO 2018.
Treatment with adjuvant trastuzumab for 6 months was noninferior to 12 months — the current standard treatment duration for HER2-positive early-stage breast cancer — in terms of disease-free survival (DFS), according to the PERSEPHONE* trial presented in ASCO 2018.
Patients who received maintenance therapy for 6 months after achieving complete remission on standard therapy for non-metastatic rhabdomyosarcoma may have better disease-free survival (DFS) and overall survival (OS) than patients who did not receive maintenance therapy, according to a phase III trial.
The use of next generation sequencing (NGS) helps guide choice of treatment in more than 30 percent of patients with acute myeloid leukaemia (AML), according to findings from a single-centre study in the US.
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).